ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

C4XD C4x Discovery Holdings Plc

11.50
-0.25 (-2.13%)
01 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
C4x Discovery Holdings Plc C4XD London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-0.25 -2.13% 11.50 16:35:10
Open Price Low Price High Price Close Price Previous Close
11.50 11.50 11.50 11.50 11.75
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

C4x Discovery C4XD Dividends History

No dividends issued between 03 Mar 2014 and 03 Mar 2024

Top Dividend Posts

Top Posts
Posted at 22/1/2024 21:07 by bloomberg2
ETX usually the poor relation!! To C4XD ....
Posted at 20/1/2024 08:49 by takeiteasy
An evolutionary year
Hunjan said that C4XD is always in discussions with potential partners as they progress their programmes along the development pathway, and partnership is something that could eventually happen with its ongoing work on IBD and other inflammatory diseases.

The company is also planning to publish results from its analysis, using PatientSeek, of two phase three clinical trials for Parkinson’s with the Garvan Institute of Medical Research.

The sheer broad range of the work being considered is what makes this such a fascinating business to link up with if you have an interest in the world of auto-immunity

dyor and no advice intended
Posted at 06/1/2024 06:54 by takeiteasy
UPDATE: Dr Julie Simmonds at Panmure Gordon commented: “C4XD has received an $11m milestone payment from AstraZeneca. We update our estimates. The payment, in addition to the divestment of the Orexin programme in July which generated £16m, means we expect the company to end the year (July) with Net Cash of £22m, the current market capitalization. C4XD is very good value with a strong drug development engine; there are few companies which have successfully developed and out-licensed three differentiated products. We reiterate our BUY recommendation.̶1;
hxxps://www.thebusinessdesk.com/northwest/news/2126285-astra-zeneca-payment-lifts-c4xd-just-as-it-hits-rock-bottom

hxxps://www.lgbco.com/quoted-landing-page/the-future-of-healthcare/c4x-discovery/
Posted at 05/1/2024 14:41 by mirabeau
DM - today

It’s fair to say C4X Discovery had a fantastic start with the shares advancing 113 per cent over the foreshortened trading week after drug giant AstraZeneca delivered an $11million post-Christmas windfall.

It came in the form of what the experts call a ‘milestone payment’ under a $402million deal with Anglo-Swedish giant, which has licensed the right to NRF2 activator, created by C4XD to tackle chronic respiratory disease.

Analysts said the payment went further than adding a material sum to the AIM company’s coffers – it provided third-party validation of the technology.

'We see this as an important value inflexion which should reinvigorate sentiment in the share,' said regional broker Shore Capital.

'Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.'
Posted at 03/1/2024 11:39 by intoodeep
News of C4X Discovery Holdings PLC (AIM:C4XD)’s latest payment from AstraZeneca PLC (LSE:AZN) solidifies and validates the company’s place as a skilled drug developer, analysts have said.

Following the firm’s update that US$11 million had been received under a deal worth up to US$400 million with AstraZeneca for the NRF2 activator programme, Shore Cap analysts backed aim-listed C4X.

“We see this as an important value inflection which should reinvigorate sentiment in the share,” the bank said in a note.

“Moreover, this serves as a timely reminder that C4XD has licensing deals in place with some of the leading developers for its programmes.”

The deal included an initial upfront payment of US$2 million to C4X and consisted of a series of developmental and commercial milestones.

Under this, C4X’s NRF2 activator programme has been out-licensed to AstraZeneca with the goal of creating an oral therapy for inflammatory and respiratory diseases.

Shore Cap added that its model for C4X suggested fair value of 52p per share, marking a prospective 480% increase on Tuesday’s closing value of 8.7p.

“These agreements serve as strong validation of C4XD’s prowess in drug discovery and demonstrate its ability to distil value from assets early in the development process,” the bank said.

Indeed, the market reacted positively to the news, with shares in C4X climbing 37% to 11.98p following the news on Wednesday morning.
Posted at 03/1/2024 09:13 by luckyabbeygale
I asume C4X may pay a great dividend in the future.
Posted at 03/1/2024 08:35 by davemac3
C4XD now looks as good as it ever has
Posted at 03/1/2024 07:35 by alanrussell
£4.2 cash at year end, since received £16m and now £11m. Say cash burn £12 pa so £4m since year end. So perhaps £27m in bank now and £19m at year end 24.
Special dividend?
Posted at 13/6/2023 22:47 by alloa2003
I dont know if anyone has noticed but PatientSeek could be a game changer for C4XD, on top of the potential drug revenues further down the line. In the test they were able to tell, using a person's DNA, which Parkinsons treatment would work best for each patient. Personal medication - the Holy Grail - with potentially massive life and cost savings for the NHS, etc.

We should be discussing this as well.
Posted at 08/6/2023 12:12 by bloomberg2
ETX work closely with C4XD !!! Something cooking

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com